Clinical trials: sponsored by Ruijin Hospital
Parkinsons Disease (PD)
Directional PSA Versus STN DBS for TD-PD
The aim of this study is to compare the effectiveness of the deep brain stimulation in the posterior subthalamic area (PSA) versus the subthalamic nucleus (STN) using directional lead for the treatment of tremor-dominant…
- Trial name
- NCT07700862
- Testing
- directional Deep brain stimulation
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Ruijin Hospital
Frontotemporal Dementia
MSC-Exosome Therapy for Frontotemporal Dementia
This study is testing a new treatment for Frontotemporal Dementia (FTD) - a progressive brain disease that affects personality, behavior, and language.
- Trial name
- NCT07638813
- Testing
- Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes （Low-Dose）, Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes （High-Dose）
- Volunteers
- 33 people
- Sponsor
- Ruijin Hospital
Parkinson's Disease, Parkinsonian Syndromes
Temporal Interference Noninvasive Deep Brain Stimulation for Idiopathic Parkinson's Disease and Parkinsonian Syndromes: Effects and Target Exploration
This study aims to explore the therapeutic effects of noninvasive deep brain electrical stimulation using temporal interference principles (Temporal Interference Stimulation, TIS) on both motor and non-motor symptoms in patients…
- Trial name
- NCT07698236
- Testing
- AB Temporal Interference Stimulation, BA Temporal Interference Stimulation
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Ruijin Hospital
Major Depressive Disorder (MDD)
6 Weeks Right-Amygdala TIS for Depression
The current investigation employs a directed neuromodulation technique, specifically targeting the right amygdala, to ascertain its therapeutic efficacy in managing depressive episodes.
- Trial name
- NCT07059143
- Testing
- Nervio-X
- Where
- 3 sites in China
- Volunteers
- 38 people
- Sponsor
- Ruijin Hospital
Coronary Artery Bypass Graft, Radial Artery Grafts
Different Anti-Spastic Therapy Strategies After CABG Using Radial Artery Grafts
The Pilot study will be a single-center, randomized, open-label, active-controlled trial. After CABG surgery using Radial Artery Grafts (RA-CABG) and signing the informed consent, all patients will be screened according to the…
- Conditions
- Coronary Artery Bypass Graft, Radial Artery Grafts, Antispastic Therapy, Pilot Study
- Trial name
- ASRAB-Pilot (NCT04310995)
- Testing
- Nicorandil 5mg tid, Diltiazem 180mg qd, Isosorbide Mononitrate 50mg qd
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Ruijin Hospital
Graft vs Host Disease
Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD
This is a prospective, multicenter, randomized controlled trial designed to evaluate whether the combination of ruxolitinib and etanercept provides superior efficacy compared with ruxolitinib monotherapy in patients with severe…
- Trial name
- RESCUE (NCT07184853)
- Testing
- Ruxolitinib (JAKAVI®), Etanercept (Enbrel)
- Where
- China
- Volunteers
- 122 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
NSCLC
SKB264 Plus Glecirasib in Advanced KRAS G12C-Mutant NSCLC: A Phase II Study
This is a multicenter, single-arm, phase II (Simon two-stage) prospective interventional clinical study. The primary objective is to evaluate the efficacy and safety of SKB264 in combination with Glecirasib (a KRAS G12C…
- Trial name
- NCT07670013
- Testing
- SKB264, Goleirex
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Local Advanced Rectal Cancer, PD-1 Inhibitor
Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial
This is a randomized, controlled clinical trial based on prior exploratory findings, designed to evaluate the efficacy and safety of neoadjuvant chemoradiotherapy combined with tafolecimab(an anti-PCSK9 inhibitor) and sintilimab…
- Conditions
- Local Advanced Rectal Cancer, PD-1 Inhibitor, PCSK9 Inhibitor, RCT
- Trial name
- NCT07686796
- Testing
- Short-course radiotherapy, CAPOX (oxaliplatin/capecitabine), Sintilimab
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Guangdong Provincial People's Hospital
Pancreatic Ductal Adenocarcinoma (PDAC)
Patient-Derived Organoid-on-a-Chip Model for Personalized Prediction of Chemotherapy Efficacy in Pancreatic Cancer
1. Background Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies worldwide, with a 5-year survival rate below 10%.
- Trial name
- NCT07683845
- Where
- China
- Volunteers
- 164 people
- Sponsor
- Beijing Daxiang Biotech Co., Ltd
Carotid Atherosclerotic Plaque
Prospective Management of Plaque Instability With Statins and Extra Folic Acid
This is a prospective, exploratory, cohort clinical study aiming to further investigate the direct impact of folic acid on the stability of carotid atherosclerotic plaques, building upon substantial clinical evidence confirming…
- Trial name
- PROMISE (NCT07680595)
- Testing
- Atorvastatin plus folic acid, Atorvastatin
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Ruijin Hospital
Breast Cancer
Ultra-Hypofractionated vs Moderate Hypofractionated Radiotherapy for Regional Lymph Nodes in High Risk Breast Cancer
For patients with breast cancer, regional nodal irradiation (RNI) can significantly reduce the risks of recurrence and mortality.
- Trial name
- HARVEST-PRO (NCT07527689)
- Testing
- Ultra-hypofractionated Regional Nodal Irradiation, Moderate Hypofractionated Regional Nodal Irradiation
- Where
- China
- Volunteers
- 1,950 people
- Sponsor
- Ruijin Hospital
Large B-cell Lymphoma
Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL
This is a Phase I/II study. The Phase I part will evaluate the safety and tolerability of sonrotoclax in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP), using a…
- Trial name
- NCT07638787
- Testing
- Polatuzumab Vedotin, Rituximab, Cyclophosphamide
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ruijin Hospital
Hematologic Malignancy, Haplo-identical HCT
CD45RA-depleted DLI for the Prevention of Viral Infections in High-risk Patients After Haploidentical Transplantation
The goal of this clinical trial is to learn whether giving patients a special type of donor immune cells (called CD45RA Depleted DLI) can help prevent viral infections after a stem cell transplant.
- Trial name
- CD45RADLIPx (NCT07672964)
- Testing
- CD45RA-depleted DLI
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Ruijin Hospital
Schizophrenia Disorders, Schizo Affective Disorder
SEEG-Guided DBS for Schizophrenia
This is a prospective, randomized, interventional study designed to evaluate the efficacy and safety of SEEG-guided deep brain stimulation (DBS) for symptom improvement in patients with treatment-resistant schizophrenia.
- Trial name
- NCT07671261
- Testing
- SEEG implantation, Deep brain stimulation
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Ruijin Hospital
Endocytoscopy
Endocytoscopy of Upper Gastrointestinal Tract in Acute Graft-versus-host Disease: a Pilot Study
The goal of this clinical trial is to test the assess the diagnostic effectiveness of endocytoscopy in patients with underlying UGI aGvHD. The main question it aims to answer is: the effectiveness of ECS for diagnosing UGI aGvHD.
- Trial name
- NCT06247891
- Testing
- ECS Group
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Ruijin Hospital
Hypertension, Grade 1
Safety and Efficacy of Renal Denervation for Untreated Grade I Hypertension: a Pilot Study
Prospective, Multi-Center, Randomized, shame-Controlled, Uptake clinical trial to evaluate the efficacy and safety of the six-channel radio-frequency（RF) renal denervation system-comprising the six-channel RF generator…
- Trial name
- STAR (NCT07664787)
- Testing
- Six-channel RF Renal Denervation System
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
Acute Myeloid Leukemia, NPM1 Mutation
Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations
This prospective, multicenter, randomized, open-label, non-inferiority clinical study aims to compare the efficacy and safety of VA regimen (venetoclax combined with azacitidine) versus conventional "3+7" chemotherapy regimen in…
- Conditions
- Acute Myeloid Leukemia, NPM1 Mutation, IDH1 Mutation, IDH2 Mutation
- Trial name
- NCT07664839
- Testing
- VEN combined with azacitidine, Cytarabine plus Daunorubicin
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Shen yang
Hematologic Malignancy, Haplo-identical HCT
CD45RA-depleted DLI for the Treatment of Refractory/Persistent Viral Infections After Haploidentical Transplantation
The goal of this clinical trial is to learn whether giving patients special donor immune cells (called "CD45RA Depleted DLI") can help treat viral infections that have not improved with standard antiviral drugs.
- Trial name
- CD45RADLITx (NCT07662369)
- Testing
- CD45RA depleted donor lymphocyte infusion (DLI)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Ruijin Hospital
Hematopoietic Malignancies, Haploidentical Hematopoietic Stem Cell Transplantation
Cousin vs. Sibling Donors in Haplo-HSCT
This observational study aims to emulate a hypothetical pragmatic, multicenter, non-blinded clinical trial enrolling adult patients undergoing haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with grafts…
- Conditions
- Hematopoietic Malignancies, Haploidentical Hematopoietic Stem Cell Transplantation, Donor
- Trial name
- NCT07662382
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- The First Affiliated Hospital of Soochow University
PTCL, T Cell Lymphoma
A Multi-center, Prospective, Registry Study to Analyze the Clinical Characteristics and Prognosis of Different Molecular Subtypes of Peripheral T-cell Lymphoma.
A multi-center, prospective, registry study to analyze the clinical characteristics and prognosis of different molecular subtypes of peripheral T-cell lymphoma.
- Trial name
- EXCELLENT (NCT07657572)
- Volunteers
- 1,000 people
- Sponsor
- Ruijin Hospital